1.The result of rehabilitation nursing of the patients with total hip replacement
Chinese Journal of Rehabilitation Medicine 2001;16(2):120-121
Objective:To understand the effect and significance of rehabilitation nursing of the patients with total hip replacement. Method:In view of the rehabilitation nursing procedure, functional training before and after the operation were performed in 34 cases with total hip replacement. Result:21 cases made completely recovery; 9 cases complete independent living ;3 cases almost independent living; l case partial dependent, and no complications. Conclusion: Scientific rehabilitation nursing plan can decrease the incidence rate of complications after the operation and promotes functional recover to patients with total hip replacement.
2.Observation on Therapeutic Efficacy of Western Medicine in Combination with Traditional Chinese Medicine for Treating Viralmyocarditis
Journal of Medical Research 2006;0(06):-
Objective To observe the therapeut ic efficacy of compound salviae m ilt io rrh igae inject ion and ast ragalus inject ion on viralmyocardit is.Methods 36 viralmyocardit patient' s were randomly divided into two groups :The control group was treated with Potassium Aspaytate and Magnesium Aspartate Injection 30ml+Insulin 8U added to 5% glucose solution 500ml and ATP 20mg+CoA 100 U+Vit C 500mg added to 10% glucose solution 30 ml for intravenous drip once daily;plus Chinese herbal medicine were taken orally in treatment group.Results The effective rates were 89.5% and 76.4% in treatment group and control group respectively.There was obvious difference between 2 groups(P
3.Green tea in chemoprevention of prostate cancer
Journal of International Oncology 2008;35(10):786-789
Green tea as a main beverage is consumed worldwide. In the last few years, .green tea has been shown to induce apoptosis and to inhibit the infiltration and metastasis of prostate cancer by in vitro and in vivo experiments. Epidemiologic investigations and clinical trials also have demonstrated the chemopreventive role of green tea in prostate cancer, such as reducing the possibility of carcinogenesis of high-grade prostatic in-traepithelial neoplasia, and is hopeful to be applied as chemopreventive agent of prostate cancer in the future.
4.Research progress of traditional Chinese medicine extract for retinal ischemia -reperfusion injury
International Eye Science 2015;(5):810-812
?Retinal ischemia - reperfusion injury ( RlRl ) is a common clinical disease, and the producing mechanism is still in research. Experimental and clinical research in recent years have showed that the mechanism of RlRl and oxygen free radicals, gene regulation, calcium overload, inflammatory cytokines and other factors are closely related. ln this article, we summarized the current situation that the scholars at home and abroad study traditional Chinese medicine extract of prevention and treatment of RlRl.
6.Inferior vena cava filter placement for the prevention of pulmonary embolism and the complications related to the filter placement
Jianming LI ; Guangzhi JIA ; Xiaojun QIN
Journal of Interventional Radiology 2009;18(12):900-903
Objective To investigate the effects of inferior vena cava (IVC) filter placement for the prevention of fatal pulmonary embolism and to discuss the management of complications related to the filter placement. Methods Seventy patients with proved deep vein thrombosis of lower extremity underwent inferior vena cava filter placement. A total of 72 IVC filters were implanted, which included 20 Trap Ease filters, 31Vena Tech filters, 13 retrievable OptEase~(TM) filters and 8 Tempo Ⅱ filters. One filter was deployed above the orifice of renal vein and the remaining 71 were deployed below the orifice of renal vein. Results All the patients were followed up for 8-72 months after the procedure. During the follow-up period no fatal pulmonary embolism occurred except that some complications related to the filter placement occurred in 6 cases.Conclusion Inferior vena cava filter placement can effectively prevent the occurrence of pulmonary embolism. Of course, this treatment should be strictly applied according to the indications.
7.Effects of presenilin-1 V97L mutation on neprilysin expressing in SH-SYSY cell
Zhe CHENG ; Wei QIN ; Jianping JIA
Chinese Journal of Neurology 2011;44(3):155-158
Objective To study the mechanisms of increasing amyloid [β1-42 (Aβ42) level by presenilin-1 (PS-1) mutation of V97L.Methods Expression level of neprilysin (NEP) in nontransfected, or mock vector, wild type (wt) PS-1 and V97L-PS-1-transfected SH-SY5Y cells were assessed by reverse transcriptional-polymerase chain reaction (RT-PCR) and Western blot.The level of Aβ42 was also assessed by enzyme linked immunosorbent assay (ELISA).Results The mRNA level of NEP was decreased significantly in PS-1 V97L transfected cells (0.650 ± 0.010) compared to that in normal cells (1.090 ± 0.015), wt PS-1 gene (1.040 ± 0.021) and mock (1.080 ± 0.020) stably transfected cell lines (t = 9.236, 10.452, 5.678; all P < 0.01).Although there was a decreased tendency in the protein expression of NEP in PS-Ⅰ V97L transfected cells (1.000 ± 0.126)compared to that in normal cells (1.020 ± 0.110), wt PS-1 gene (1.040 ±0.110), mock (2.130 ±0.130) stably transfected cell lines, nosignificant differences were found.The expression of Aβ42 was increased significantly in PS-1 V97L transfected cells compared to other cell lines (t = 2.109, 3.355, 3.976; all P < 0.01).Conclusions PS-1 V97L mutation can decrease the transcription of NEP, however, in contrast, this mutation also resulted in increased Aβ42.The mechanism needs further analysis.
8.Research progress of Yttrium-90 in the treatment of unresectable and chemotherapy-tolerant colorectal liver metastasis
Zhongzhi JIA ; Chunfu ZHU ; Xihu QIN
Chinese Journal of Digestive Surgery 2016;15(2):200-202
Colorectal liver metastasis (CRLM) is a common liver metastatic tumor with poor prognosis.It was very difficult to treat patients with unresectable and chemotherapytolerant CRLM.With the tumor control rate ranging from 63% to 78%,Yttrium-90 is both safe and effective in treating unresectable and chemotherapy-tolerant CRLM.The median survival time is 10.5 months,and the 1-,2-,3-year overall survival rates of patients are 44%,20% and 14% respectively.For a certain portion of patients,Yttrium-90 has distinct advantages over mo lecular targeted drugs and other local minimally invasive treatment.Though Yttrium-90 treatment has showed certain curative effect,its safety and effectiveness require further confirmation through multi-center randomized controlled trial.
9.Clinical observation of arsenic trioxide plus all trans retinoic acid versus ATRA combined with chemotherapy treatment on acute promyelocytic leukemia
Jia WAN ; Dabing QIN ; Jieping CHEN
Chongqing Medicine 2014;(31):4185-4187
Objective To observe the efficacy of arsenic trioxide(ATO) combined all trans retinoic acid (ATRA) versus cytara‐bine (Ara‐C) combined ATRA in the treatment of acute promyelocytic leukemia(APL) .Methods We enrolled 65 patients in our department during the period between January 2002 and August 2008 ,and they were randomly assigned to receive ATRA combined ATO (treatment group ,n= 27) or ATRA combined DA ,HA ,NA which were major of Ara‐C (control group ,n= 38) .Then observe the differences of between the two groups ,such as complete remission(CR) ,the time to complete remission ,overall survival(OS) ,e‐vent free survival(EFS) ,the 5 years disease free survival (DFS) and adverse reactions .Results The CR rate of treatment group (ATRA + ATO) and control group (chemotherapy + ATRA) was 81 .48% and 68 .42% ,respectively ,and the time to complete re‐mission was (28 .50 ± 3 .97)d and (30 .56 ± 2 .39)d ,respectively ,showed that there was no statistical difference between the two groups ( P > 0 .05 ) .The 5 years DFS of the CR patients in the two groups was 51 .9% (ATRA + ATO ) and 50 .0%(Chemotherapy + ATRA) ,respectively ,showed that there was no statistical difference between the two groups(P > 0 .05) .The 5 years EFS of the CR patients in the two groups was 48 .1% and 39 .5% ,respectively ,showed that there was no statistical difference between the two groups(P> 0 .05) .The 5 years DFS of the patients in the two groups was 55 .6% and 67 .6% ,respectively ,showed that there was no statistical difference between the two groups(P > 0 .05) .Bone marrow suppression in the treatment group was significantly lower than in the control group(P< 0 .05) .Conclusion ATRA + ATO can prolong the CR rate ,OS ,EFS and 5 years EFS of newly diagnosed APL patients .ATRA combined with chemotherapy has similar efficacy ,ATRA + ATO has lower bone marrow suppression than the ATRA combined with chemotherapy ,thus may reduce the risk of early death .
10.Cloning and expression of immunotoxin DT389- hbFGF
Lian-Rong, YIN ; Jia-Qin, YUAN
International Eye Science 2007;7(1):15-18
AIM: To express the DT389-hbFGF (389 amino acid residues of the N-terminus of diphtheria toxin (human basic fibroblast growth factor) fusion protein for potential targeting therapy towards posterior capsule opacification (PCO) after cataract surgery.METHODS: The DNA of inactivated diphtheria bacillus and RNA of 12-week fetal brain cortex were extracted, respectively. The fragments of truncated diphtheria toxin (containing 389 amino acids of N-terminus, DT389) )and full-length human basic fibroblast growth factor(hbFGF) sequence (encoding 18kDa protein) were amplified by PCR. The two fragments were inserted into pGEX-4T-1 prokaryotic expression vector to obtain pGEX-DT389-hbFGF prokaryotic expression plasmid. After sequence analysis, the expressing plasmid was transformed into Escherichia Coli BL21 strain and expression was induced under IPTG. The expressed fusion protein was purified and identified.RESULTS: The gene fragments encoding DT389 and hbFGF were amplified and their gene sequences were confirmed. Hybrid gene expression plasmid pGEX-DT389 (hbFGF was constructed. The fusion protein DT389-hbFGF was expressed and purified.CONCLUSIONS: The successful cloning and expression of DT389-hbFGF immunotoxin provides a foundation for targeting therapy towards posterior capsule opacification.